Category: Uncategorized

LEAD Coalition submits comments on Congressional framework for reforming the NIH

The LEAD Coalition has submitted a letter providing input on House Energy and Commerce Committee Chair Cathy McMorris Rodgers’ “Reforming the National Institutes of Health Framework for Discussion.” The LEAD Coalition letter encourages a congressional process that ensures Alzheimer’s disease and related disorders research continues to be addressed collaboratively across NIH with a life-course, person-centered […]

LEAD Coalition submits public comments for FDA review of donanemab

Today, 265 LEAD Coalition member organizations and allies sent a joint public comment letter to the U.S. Food and Drug Administration (FDA) regarding its review of the supplemental biologics license application for donanemab (BLA 761248) for the treatment of mild cognitive impairment and early dementia due to Alzheimer’s disease. The letter expresses full confidence in […]